About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (OP:TLTFF)

0.1345 -0.0056 (-4.00%)
Streaming Delayed Price Updated: 1:56 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,323
Open 0.1379
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1401
Today's Range 0.1295 - 0.1379
52wk Range 0.1019 - 0.3061
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Theralase(R) Releases Q2 2026 Financial Statements
Theralase(R) Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline 
Via Newsfile
News headline image
Theralase(R) Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile

Performance

YTD
+1.9%
+1.9%
1 Month
-1.2%
-1.2%
3 Month
-21.6%
-21.6%
6 Month
-32.7%
-32.7%
1 Year
-1.5%
-1.5%

More News

Read More
News headline image
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Via Newsfile
News headline image
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Via Newsfile
News headline image
Theralase(R) Lists Warrants on the TSXV
Via Newsfile
News headline image
Theralase(R) Releases Q1 2026 Financial Statements
Via Newsfile
News headline image
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Via Newsfile
News headline image
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Via Newsfile
News headline image
Theralase(R) Closes $CAN 2.66 Million Financing
Via Newsfile
News headline image
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Via Newsfile
News headline image
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Via Newsfile
News headline image
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Via Newsfile
News headline image
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Via Newsfile
News headline image
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress ↗
Via Newsfile
News headline image
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Via Newsfile
News headline image
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Via Newsfile
News headline image
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
Via Newsfile
News headline image
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
Via Newsfile
News headline image
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Via Newsfile
News headline image
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Via Newsfile
News headline image
Theralase(R) Investor Conference Call Reminder
Via Newsfile
News headline image
Theralase(R) Releases 3Q2025 Financial Statements
Via Newsfile
News headline image
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
Via Newsfile
News headline image
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Via Newsfile
Topics Derivatives
News headline image
Theralase(R) Extends Warrants
Via Newsfile

Frequently Asked Questions

Is Theralase Technologies Inc publicly traded?
Yes, Theralase Technologies Inc is publicly traded.
What exchange does Theralase Technologies Inc trade on?
Theralase Technologies Inc trades on the OTC Traded
What is the ticker symbol for Theralase Technologies Inc?
The ticker symbol for Theralase Technologies Inc is TLTFF on the OTC Traded
What is the current price of Theralase Technologies Inc?
The current price of Theralase Technologies Inc is 0.1345
When was Theralase Technologies Inc last traded?
The last trade of Theralase Technologies Inc was at 09/10/26 01:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.